Literature DB >> 33047190

Effect of periosteal reaction in medication-related osteonecrosis of the jaw on treatment outcome after surgery.

Sakiko Soutome1, Souichi Yanamoto2, Misa Sumi3, Saki Hayashida4, Yuka Kojima5, Shunsuke Sawada5, Satoshi Rokutanda6, Hiroshi Iwai7, Toshiyuki Saito1, Masahiro Umeda4.   

Abstract

INTRODUCTION: Surgical treatment in patients with medication-related osteonecrosis of the jaw (MRONJ) is superior to conservative treatment. However, treatment outcome in patients with periosteal reaction (PR) was significantly poorer than that of those without PR. The purpose of this retrospective study was to analyze the pathophysiology and clinical significance of PR in MRONJ.
MATERIALS AND METHODS: Out of 181 patients with MRONJ undergoing surgery, 38 patients with PR were enrolled in the study. CT examinations, histological examinations, and bacteriological examinations using real-time polymerase chain reaction were performed, and the relationship among the opted surgical method, CT findings, and treatment outcome was investigated.
RESULTS: The pattern of PR was classified into three types: type 1, new bone is formed parallel to the mandible, and no gap was evident between the mandible and new bone; type 2, new bone is formed parallel to the mandible, and a gap was evident between them; type 3, an irregular shape. Histological examinations revealed inflammatory tissue in the area visualized as a gap on CT. Bacteriological examination showed the presence of bacteria in the type 2 or type 3 PR. Complete cure was observed in 21 of 38 (55.3%) patients, which was lower than the cure rate of 73.4% in 143 patients without PR. The cure rate was significantly lower in cases with type 3 PR or with persistent osteolysis.
CONCLUSIONS: It seems that complete resection of both osteolytic area and type 3 PR is necessary to obtain complete healing in patients undergoing marginal mandibulectomy.

Entities:  

Keywords:  Antiresorptives; Clinical trials; Dental biology; Osteoporosis; Radiology

Mesh:

Substances:

Year:  2020        PMID: 33047190     DOI: 10.1007/s00774-020-01154-6

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  5 in total

1.  Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy.

Authors:  Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Souichi Yanamoto; Miho Sasaki; Yukinori Takagi; Misa Sumi; Yuka Kojima; Shunsuke Sawada; Hiroshi Iwai; Masahiro Umeda; Toshiyuki Saito
Journal:  Support Care Cancer       Date:  2021-04-21       Impact factor: 3.603

2.  Retrospective Analysis of Treatment Outcomes of Maxillary Sinusitis Associated with Medication-Related Osteonecrosis of the Jaw.

Authors:  Mitsunobu Otsuru; Saki Hayashida; Kota Morishita; Maho Murata; Sakiko Soutome; Miho Sasaki; Yukinori Takagi; Misa Sumi; Masahiro Umeda
Journal:  Int J Environ Res Public Health       Date:  2022-06-17       Impact factor: 4.614

Review 3.  Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review.

Authors:  Pongsapak Wongratwanich; Kiichi Shimabukuro; Masaru Konishi; Toshikazu Nagasaki; Masahiko Ohtsuka; Yoshikazu Suei; Takashi Nakamoto; Rinus G Verdonschot; Tomohiko Kanesaki; Pipop Sutthiprapaporn; Naoya Kakimoto
Journal:  Dentomaxillofac Radiol       Date:  2021-01-15       Impact factor: 3.525

4.  A preliminary clinical study of segmental mandibulectomy on medication-related osteonecrosis of the jaw.

Authors:  Mitsunobu Otsuru; Sakiko Soutome; Saki Hayashida; Satoshi Rokutanda; Souichi Yanamoto; Masahiro Umeda
Journal:  J Dent Sci       Date:  2021-08-26       Impact factor: 2.080

5.  Factors Exacerbating Clinical Symptoms and CT Findings in Patients with Medication-Related Osteonecrosis of the Jaw Receiving Conservative Therapy: A Multicenter Retrospective Study of 53 Cases.

Authors:  Yuka Kojima; Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Yuki Sakamoto; Shunsuke Sawada; Masahiro Umeda
Journal:  Int J Environ Res Public Health       Date:  2022-06-26       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.